PCM
PHAT icon

Prelude Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Prelude Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,044
Closed -$234K – 1428
2024
Q1 		$234K Buy
+22,044
New +$187K 0.01% 1026

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Prelude Capital Management's PHAT Position: Q2 2024 in Review

Prelude Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q2 2024, closing a stake of 22,044 shares — an estimated $234K sold.

Prelude Capital Management first reported a position in PHAT in Q1 2024 and held it in 1 quarter. The position peaked at $234K in Q1 2024. 114 funds tracked by Wall St. Rank hold PHAT as of Q2 2024.

  • Prelude Capital Management reported no remaining Phathom Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Prelude Capital Management sold 22,044 Phathom Pharmaceuticals shares in Q2 2024, an estimated $234K.
  • Prelude Capital Management first reported a position in Phathom Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Prelude Capital Management's Phathom Pharmaceuticals position peaked at $234K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.